Company overview
Cyprumed is an Austria-based drug delivery company specializing in proprietary platforms for non-invasive oral administration of biologics, peptides like GLP-1 agonists, and BCS Class IV drugs. Their technology offers superior bioavailability, IP protection, scalable tablet formulations, and has demonstrated up to 70% relative oral bioavailability in preclinical studies. Recent partnerships, including a non-exclusive license with MSD (Merck & Co.) for oral peptide therapeutics, highlight their platform's potential.
Oral Peptide Delivery is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include oral peptide delivery, drug delivery platform, glp-1 oral formulation, bcs class iv delivery, non-invasive biologics.
Structured facts
- Website
- https://www.cyprumed.net
- Markets served
- United States & Americas
- Keywords
- oral peptide delivery, drug delivery platform, glp-1 oral formulation, bcs class iv delivery, non-invasive biologics
Products & technologies
Therapeutic areas
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What drug delivery technologies does Cyprumed offer?
- Cyprumed provides proprietary oral delivery platforms for peptides such as GLP-1 agonists and BCS Class IV drugs, featuring superior bioavailability, IP protection, scalable tablet formulations, and up to 70% relative oral bioavailability in preclinical rodent, dog, and non-human primate studies.
- What are Cyprumed's regulatory and IP capabilities?
- Cyprumed's technology uses GRAS-listed compounds, offers IP protection and freedom-to-operate, and holds patents like US10905744B2 for oral peptide formulations. They have licensed their platform non-exclusively to MSD with options for exclusivity.
- Where is Cyprumed located and what are their partnership experiences?
- Cyprumed is based in Innsbruck, Austria, with operations also noted in Obsteig. They entered a major license agreement with MSD (Merck & Co.) in April 2025, potentially worth up to $493 million in milestones for oral peptide development.
Related editorial coverage
- $2M Gene Therapy Cures Need a Financing Model
- A Secure And Intelligent Drug Delivery Model Integrating Neural Networks With Blockchain
- AACR 2024: Daily Oncology Research Roundup
- AACR 2024: Oncology News & Key Takeaways - Day 1
- AACR 2024: Oncology Research Highlights - Day 1 Roundup
- AACR 2026: AI Pathology & Oncolytic Virus Spark Interest
Explore lab tools and QA/QC resources for R&D teams.
